News Napp launches Neulasta biosimilar in UK Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following
Oncology Has the NHS joined the biosimilars revolution? Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face